Immunotherapy has been a remarkable clinical advancement in the treatment of cancer. T
cells are pivotal to the efficacy of current cancer immunotherapies, including immune …

Ten years since the immune checkpoint inhibitor ipilimumab was approved for advanced
melanoma, it is time to reflect on the lessons learned regarding modulation of the immune …

Fecal microbiota transplantation (FMT) represents a potential strategy to overcome
resistance to immune checkpoint inhibitors in patients with refractory melanoma; however …

Cancer immunity, and the potential for cancer immunotherapy, have been topics of scientific
discussion and experimentation for over a hundred years. Several successful cancer …

Recent advances in cancer immunotherapy—ranging from immune-checkpoint blockade
therapy to adoptive cellular therapy and vaccines—have revolutionized cancer treatment …

Improvements in tumor immunotherapies depend on better understanding of the anti-tumor
T cell response. By studying human tumor-draining lymph nodes (TDLNs), we found that …

Anti–programmed cell death protein 1 (PD-1) therapy provides long-term clinical benefits to
patients with advanced melanoma. The composition of the gut microbiota correlates with anti …

Immune checkpoint inhibitors (ICIs) have made an indelible mark in the field of cancer
immunotherapy. Starting with the approval of anti-cytotoxic T lymphocyte-associated protein …

In December 2019, a novel coronavirus was isolated from the respiratory epithelium of
patients with unexplained pneumonia in Wuhan, China. This pathogen, named severe acute …

Neoadjuvant immune checkpoint blockade has shown promising clinical activity. Here, we
characterized early kinetics in tumor-infiltrating and circulating immune cells in oral cancer …